The Danish brewer Carlsberg A/S has said that it is to up its investment in the biotech sector by over 100m Danish crowns (US$13.3m). The company's biotech interest stems from the group's continuing research into enzymes for the beer industry, it said. "It's a natural way for us to invest," Carlsberg Chief Executive Officer Joern P. Jensen told a news conference.